China Resources Pharmaceutical Group Ltd

Chart & Performance

D1W1MN

P/E

8.97

P/S

0.13

EPS

0.61

Div Yield, %

2.81%

Shrs. gr., 5y

-0.01%

Rev. gr., 5y

7.35%

Revenues

270.40b

+6.41%

Net income

3.85b

+10.11%

CFO

15.55b

+42.68%

Dividend

Sep 10, 20240.0908 HKD/sh

Earnings

Mar 24, 2025

Profile

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and Hong Kong. The company operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. It offers a range of chemical drugs, Chinese medicines, and biopharmaceutical drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular, alimentary tract, metabolism and endocrine, respiratory, orthopedics, oncology, medical nutrition, gastroenterology, pediatrics, genitourinary system, cough and cold, anti-infection, dermatology, infusion solutions, etc. The company also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, it is involved in property holding activities. As of December 31, 2021, the company operated 801 retail pharmacies under the CR Care and Teck Soon Hong brands. It distributes its products to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

URL

https://www.crpharm.com/

IPO date

Oct 28, 2016

Employees

71,000

Domiciled in

Incorporated in

Valuation

Order:

Title HKD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title HKD in thousands, except ratios and share amounts	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12	2014‑12
Income
Revenues	270,397,302 6.41%	254,106,366 7.31%	236,806,169 18.15%
Cost of revenue	254,880,089	242,572,804	226,872,781
Unusual Expense (Income)
NOPBT	15,517,213	11,533,562	9,933,388
NOPBT Margin	5.74%	4.54%	4.19%
Operating Taxes	2,105,224	2,012,402	1,761,026
Tax Rate	13.57%	17.45%	17.73%
NOPAT	13,411,989	9,521,160	8,172,362
Net income	3,854,247 10.11%	3,500,270 13.62%	3,080,673 10.87%
Dividends	(972,360)	(942,377)	(753,902)
Dividend yield	3.02%	2.37%	3.38%
Proceeds from repurchase of equity	(516,835)	2,874,996	(777,825)
BB yield	1.60%	-7.24%	3.49%
Debt
Debt current	46,223,589	56,013,044	74,474,489
Long-term debt	17,245,795	10,984,525	8,113,091
Deferred revenue	788,581	867,753	890,778
Other long-term liabilities	1,118,654	1,150,113	1,327,349
Net debt	31,940,222	21,328,042	34,216,044
Cash flow
Cash from operating activities	15,549,886	10,898,714	11,220,436
CAPEX	(3,461,644)	(3,356,325)	(2,902,867)
Cash from investing activities	(2,067,287)	(3,298,386)	(8,832,670)
Cash from financing activities	(4,472,401)	(9,001,601)	5,313,092
FCF	38,294,587	25,143,697	(39,541,347)
Balance
Cash	59,266,387	32,522,319	37,315,677
Long term investments	(27,737,225)	13,147,208	11,055,859
Excess cash	18,009,297	32,964,209	36,531,228
Stockholders' equity	102,324,859	90,182,333	94,984,266
Invested Capital	163,958,828	125,491,987	142,323,276
ROIC	9.27%	7.11%	7.12%
ROCE	8.46%	7.20%	5.49%
EV
Common stock shares outstanding	6,282,510	6,282,510	6,282,510
Price	5.13 -18.83%	6.32 78.03%	3.55 -11.03%
Market cap	32,229,279 -18.83%	39,705,466 78.03%	22,302,912 -11.04%
EV	115,892,590	101,656,422	100,521,735
EBITDA	19,013,830	14,685,712	12,755,278
EV/EBITDA	6.10	6.92	7.88
Interest	2,386,312	2,855,820	2,712,386
Interest/NOPBT	15.38%	24.76%	27.31%